Early Flt3L clinical trials failed to induce anti-tumor immunity50,51, likely attributable to the tolerogenicity of immature DCs52; however, recent trials show that only the combination of Flt3L and DC activators (e.g. TLRa) yield potent Ag-specific T cell responses53. Here, FLT3LG is linked to neoplasm.